Sipuleucel-T: Autologous Cellular Immunotherapy for Men with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer

Sims, Robert B.

doi:10.7150/jca.2.357

International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

open access Global reach, higher impact

Full Text | PDF

J Cancer 2011; 2:357-359. doi:10.7150/jca.2.357 This volume Cite

Short Report

Sipuleucel-T: Autologous Cellular Immunotherapy for Men with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer

Robert B. Sims^✉

Dendreon Corporation, Seattle, WA, USA

Citation:

Sims RB. Sipuleucel-T: Autologous Cellular Immunotherapy for Men with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer. J Cancer 2011; 2:357-359. doi:10.7150/jca.2.357. https://www.jcancer.org/v02p0357.htm

Other styles

Abstract

Sipuleucel T is an autologous cellular immunotherapy designed to stimulate an immune response in men diagnosed with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. Sipuleucel T improves overall survival and provides an additional treatment option for this patient population.

Keywords: sipuleucel-T, metastatic castrate resistant prostate cancer (mCRPC)

Citation styles

APA

Sims, R.B. (2011). Sipuleucel-T: Autologous Cellular Immunotherapy for Men with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer. Journal of Cancer, 2, 357-359. https://doi.org/10.7150/jca.2.357.

ACS

Sims, R.B. Sipuleucel-T: Autologous Cellular Immunotherapy for Men with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer. J. Cancer 2011, 2, 357-359. DOI: 10.7150/jca.2.357.

NLM

CSE

Sims RB. 2011. Sipuleucel-T: Autologous Cellular Immunotherapy for Men with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer. J Cancer. 2:357-359.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.